Open this publication in new window or tab >>Show others...
2025 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 16, article id 1705805Article in journal (Refereed) Published
Abstract [en]
With antibiotic resistance being a major global concern, there is a huge need of new treatment options to fight bacterial infections. In this study, we highlight the antibacterial and host-protective roles of a novel synthetic antimicrobial peptide in uropathogenic Escherichia coli–infected uroepithelial cells. This peptide, designed from a fragment of human cathelicidin LL-37 and named LD4-PP, was found to be highly potent against clinical isolates of E. coli as well as ESBL-producing and multi-drug resistant E. coli. Additionally, LD4-PP inhibited the formation of new biofilm, damaging both the bacterial surface and the bacterial genome. LD4-PP also modulated the host cell lipid vacuole, caveolin-1, and Rho GTPase B affecting bacterial survival. Furthermore, LD4-PP exerts immunomodulatory effects by modulating free radical formation, expression of antioxidants, and inflammasome-mediated cell death. Pronounced uroepithelial cell death was observed after E. coli infection which was significantly inhibited by LD4-PP without affecting the cellular toxicity. Overall, the peptide LD4-PP is shown to be a strong candidate for future clinical applications, particularly to prevent and treat urinary tract infections.
Place, publisher, year, edition, pages
Frontiers Media S.A., 2025
Keywords
E. coli, synthetic antimicrobial peptide, immune response, urinary tract infection, innate immunity
National Category
Infectious Medicine
Research subject
Microbiology
Identifiers
urn:nbn:se:oru:diva-125500 (URN)10.3389/fimmu.2025.1705805 (DOI)001639802500001 ()41415272 (PubMedID)2-s2.0-105025171786 (Scopus ID)
Funder
Region StockholmThe Karolinska Institutet's Research FoundationSwedish Research Council, 2023-04909Swedish Research Council, 2018–03318Swedish Research Council, 2023-05530
Note
Funding:
Swedish Neurological Association
2025-12-082025-12-082026-01-23Bibliographically approved